

Case Docket No. DECLE55.1CP2DV

Date: September 16, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Moser et al.	attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed
App. No.	:	09/802,397	to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on
Filed	:	March 9, 2001	September 16, 2002 (Date) September 16, 2002 (Date)
For	:	DENDRITIC-LIKE	Catherine M. Sanders, Reg. No. 50,660
		CELL/TUMOR CELL	·)
		HYBRIDS AND)
		HYBRIDOMAS FOR) PEOE
		INDUCING AN ANTI-	RECEIVED
		TUMOR RESPONSE)
			SEP 2 5 2002
Group Art Unit	: :	1636	TECH OF NTER 1000
			TECH CENTER 1600/2900

TRANSMITTAL LETTER

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In response to the Notice to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures which was mailed by the Office on June 17, 2002, enclosed are:

- An Amendment and Sequence Submission Statement. (X)
- A paper copy of the Sequence Listing. (X)
- A computer readable Sequence Listing disk. (X)
- An extension of time to respond for two months is hereby requested. (X)

Time Extension Fee:

0	one month	(\$110 large entity)
(X)	two months	(\$400 large entity)
0	three months	(\$920 large entity)

09/23/2002 SMINASS1 00000066 09802397

Case Docket No. DECLE55.1CP2DV

Date: September 16, 2002

- Return prepaid postcard. (X)
- A check in the amount of \$400.00 to cover the above fees is enclosed. (X)
- The Commissioner is hereby authorized to charge any additional fees which may be (X) required, now or in the future, or credit any overpayment, to Account No. 11-1410.

Catherine M. Sanders Registration No. 50,660

Agent of Record

H:\DOCS\CMS\CMS-3033.DOC:jd 091602

Application No.: 09/802

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLECTION SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

内	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	RECEIVED
	7. Other: SEP \$ 2002
	7. Other: 5 2002
	7. Other:
	7. Other:
X	7. Other: SEP \$ 5 2002 SIGNATE Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry.
X	7. Other: SEP \$ 5 2002 Flicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry nto the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1,821(e) or 1,821(f) or 1,821(g) or

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY